General form of registration statement for all companies including face-amount certificate companies

Commitments and Contingencies (Details)

v3.23.2
Commitments and Contingencies (Details)
£ in Millions
 1 Months Ended 9 Months Ended 12 Months Ended
Dec. 20, 2022
item
Jun. 04, 2021
lawsuit
Dec. 31, 2019
USD ($)
Feb. 28, 2023
USD ($)
May 31, 2022
USD ($)
item
D
May 31, 2022
GBP (£)
Jan. 31, 2022
USD ($)
Jan. 06, 2022
USD ($)
Shareholder Derivative Lawsuits                
Commitments and Contingencies                
Consolidated number of lawsuits | lawsuit   3            
Securities and Exchange Commission and Department of Justice Investigations | Mr. Pourhassan                
Commitments and Contingencies                
Number of conspiracy charges | item 1              
Number of security fraud charges | item 4              
Number of wire fraud charges | item 3              
Number of insider trading charges | item 3              
Securities and Exchange Commission and Department of Justice Investigations | Kazem Kazempour                
Commitments and Contingencies                
Number of conspiracy charges | item 1              
Number of security fraud charges | item 3              
Number of wire fraud charges | item 2              
Number of insider trading charges | item 1              
Samsung BioLogics Co., Ltd. ("Samsung")                
Commitments and Contingencies                
Forecast period       3 years 3 years      
Amount of material breach of' Master Services and Project Specific Agreements               $ 13,500,000
Additional Contractual Obligation             $ 22,800,000  
Past due balance       $ 232,788,000 $ 232,788,000      
Fiscal Year                
2023 (3 months remaining)       34,638,000 34,638,000      
2024       121,750,000 121,750,000      
2025       76,400,000 76,400,000      
Total       232,788,000 $ 232,788,000      
License Agreements With Vyera Pharmaceuticals, LLC                
Commitments and Contingencies                
Amount payable upon achievement of sales and regulatory milestone     $ 85,300,000          
Percentage of royalty payable by the counter party     50.00%          
Term of arrangement     10 years          
Term of arrangement, after first commercial sale     2 years          
Number of days of prior written notice | D         180      
Progenics Purchase Agreement [Member]                
Commitments and Contingencies                
Amount of milestone payments payable         $ 5,000,000      
Percentage of royalty payable         3.50%      
Amount payable upon filing BLA with FDA         $ 500,000      
Amount payable upon FDA approval         500,000      
Annual maintenance fees         $ 150,000      
Progenics Purchase Agreement [Member] | Royalty Payable in Initial 10 Years [Member]                
Commitments and Contingencies                
Percentage of royalty payable         5.00%      
Lonza Agreement                
Commitments and Contingencies                
Number of contract manufacturers | item         2      
Annual license fee         $ 700,000 £ 0.6    
Royalty on net sales (as a percent)         2.00% 2.00%    
Accounts Payable | Samsung BioLogics Co., Ltd. ("Samsung")                
Commitments and Contingencies                
Past due balance       34,300,000 $ 38,100,000      
Fiscal Year                
Total       $ 34,300,000 $ 38,100,000